Cargando…

Intravitreal Voriconazole for the Treatment of Cryptococcus neoformans Endogenous Endophthalmitis

Background: Cryptococcus neoformans is an encapsulated yeast that can cause fungemia and, in rare instances, lead to endogenous fungal endophthalmitis. No standard of care has been established to treat fungal endophthalmitis when systemic antifungal treatment fails to resolve the intraocular infecti...

Descripción completa

Detalles Bibliográficos
Autores principales: Haider, Asghar A., Gallagher, J. R., Johnson, Jordan S., Benevento, Joseph D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academic Division of Ochsner Clinic Foundation 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7529130/
https://www.ncbi.nlm.nih.gov/pubmed/33071668
http://dx.doi.org/10.31486/toj.19.0043
_version_ 1783589371614593024
author Haider, Asghar A.
Gallagher, J. R.
Johnson, Jordan S.
Benevento, Joseph D.
author_facet Haider, Asghar A.
Gallagher, J. R.
Johnson, Jordan S.
Benevento, Joseph D.
author_sort Haider, Asghar A.
collection PubMed
description Background: Cryptococcus neoformans is an encapsulated yeast that can cause fungemia and, in rare instances, lead to endogenous fungal endophthalmitis. No standard of care has been established to treat fungal endophthalmitis when systemic antifungal treatment fails to resolve the intraocular infection. Intravitreal voriconazole has been used for the treatment of fungal endophthalmitis caused by a broad range of fungal pathogens, and a limited number of reports have shown the efficacy of using intravitreal voriconazole for C neoformans endophthalmitis. We report a case of endogenous fungal endophthalmitis caused by C neoformans that was responsive to intravitreal voriconazole. Case Report: A previously healthy 57-year-old male diagnosed with primary neuroendocrine lung tumor developed endogenous endophthalmitis from C neoformans. The endophthalmitis was resistant to intravenous amphotericin B treatment but was responsive to intravenous fluconazole in one eye and was apparently more responsive to intravitreal voriconazole in the other eye. Conclusion: Intravitreal voriconazole should be considered for the treatment of cryptococcal endophthalmitis.
format Online
Article
Text
id pubmed-7529130
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Academic Division of Ochsner Clinic Foundation
record_format MEDLINE/PubMed
spelling pubmed-75291302020-10-15 Intravitreal Voriconazole for the Treatment of Cryptococcus neoformans Endogenous Endophthalmitis Haider, Asghar A. Gallagher, J. R. Johnson, Jordan S. Benevento, Joseph D. Ochsner J Case Reports and Clinical Observations Background: Cryptococcus neoformans is an encapsulated yeast that can cause fungemia and, in rare instances, lead to endogenous fungal endophthalmitis. No standard of care has been established to treat fungal endophthalmitis when systemic antifungal treatment fails to resolve the intraocular infection. Intravitreal voriconazole has been used for the treatment of fungal endophthalmitis caused by a broad range of fungal pathogens, and a limited number of reports have shown the efficacy of using intravitreal voriconazole for C neoformans endophthalmitis. We report a case of endogenous fungal endophthalmitis caused by C neoformans that was responsive to intravitreal voriconazole. Case Report: A previously healthy 57-year-old male diagnosed with primary neuroendocrine lung tumor developed endogenous endophthalmitis from C neoformans. The endophthalmitis was resistant to intravenous amphotericin B treatment but was responsive to intravenous fluconazole in one eye and was apparently more responsive to intravitreal voriconazole in the other eye. Conclusion: Intravitreal voriconazole should be considered for the treatment of cryptococcal endophthalmitis. Academic Division of Ochsner Clinic Foundation 2020 2020 /pmc/articles/PMC7529130/ /pubmed/33071668 http://dx.doi.org/10.31486/toj.19.0043 Text en ©2020 by the author(s); Creative Commons Attribution License (CC BY) http://creativecommons.org/licenses/by/4.0/legalcode ©2020 by the author(s); licensee Ochsner Journal, Ochsner Clinic Foundation, New Orleans, LA. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (creativecommons.org/licenses/by/4.0/legalcode) that permits unrestricted use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
spellingShingle Case Reports and Clinical Observations
Haider, Asghar A.
Gallagher, J. R.
Johnson, Jordan S.
Benevento, Joseph D.
Intravitreal Voriconazole for the Treatment of Cryptococcus neoformans Endogenous Endophthalmitis
title Intravitreal Voriconazole for the Treatment of Cryptococcus neoformans Endogenous Endophthalmitis
title_full Intravitreal Voriconazole for the Treatment of Cryptococcus neoformans Endogenous Endophthalmitis
title_fullStr Intravitreal Voriconazole for the Treatment of Cryptococcus neoformans Endogenous Endophthalmitis
title_full_unstemmed Intravitreal Voriconazole for the Treatment of Cryptococcus neoformans Endogenous Endophthalmitis
title_short Intravitreal Voriconazole for the Treatment of Cryptococcus neoformans Endogenous Endophthalmitis
title_sort intravitreal voriconazole for the treatment of cryptococcus neoformans endogenous endophthalmitis
topic Case Reports and Clinical Observations
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7529130/
https://www.ncbi.nlm.nih.gov/pubmed/33071668
http://dx.doi.org/10.31486/toj.19.0043
work_keys_str_mv AT haiderasghara intravitrealvoriconazoleforthetreatmentofcryptococcusneoformansendogenousendophthalmitis
AT gallagherjr intravitrealvoriconazoleforthetreatmentofcryptococcusneoformansendogenousendophthalmitis
AT johnsonjordans intravitrealvoriconazoleforthetreatmentofcryptococcusneoformansendogenousendophthalmitis
AT beneventojosephd intravitrealvoriconazoleforthetreatmentofcryptococcusneoformansendogenousendophthalmitis